MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
3.920
+0.050 (1.29%)
At close: Jun 17, 2026, 4:00 PM EDT
3.880
-0.040 (-1.02%)
After-hours: Jun 17, 2026, 6:20 PM EDT
MannKind Revenue
MannKind had revenue of $90.17M in the quarter ending March 31, 2026, with 15.08% growth. This brings the company's revenue in the last twelve months to $360.78M, up 21.23% year-over-year. In the year 2025, MannKind had annual revenue of $348.97M with 22.23% growth.
Revenue (ttm)
$360.78M
Revenue Growth
+21.23%
P/S Ratio
3.36
Revenue / Employee
$609,431
Employees
592
Market Cap
1.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 348.97M | 63.46M | 22.23% |
| Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
| Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
| Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
| Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
| Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
| Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
| Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
| Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
| Dec 31, 2016 | 174.76M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Maravai LifeSciences Holdings | 204.73M |
| Wave Life Sciences | 71.80M |
| Immatics | 43.00M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 10.00M |
| Aktis Oncology | 8.28M |
| Absci | 1.84M |
MNKD News
- 11 days ago - Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems - GlobeNewsWire
- 14 days ago - MannKind Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 14 days ago - MannKind announces milestones in development of nintedanib DPI for IPF - TheFly
- 14 days ago - MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF - GlobeNewsWire
- 16 days ago - MannKind price target raised to $11 from $10 at Wells Fargo - TheFly
- 19 days ago - MannKind Transcript: FDA announcement - Transcripts
- 19 days ago - MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - GlobeNewsWire
- 19 days ago - US FDA approves MannKind's inhaled insulin for children - Reuters